Early Diabetes Intervention Trial

Submission date 19/06/2002	Recruitment status No longer recruiting
Registration date 19/06/2002	Overall study status Completed
Last Edited 06/01/2011	Condition category Nutritional, Metabolic, Endocrine

[] Prospectively registered

[] Protocol

[] Statistical analysis plan

[X] Results

[] Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

http://www.dtu.ox.ac.uk/edit/protocol.php

Contact information

Type(s) Scientific

Contact name Dr Rury R Holman

Contact details

Diabetes Trials Unit OCDEM, Churchill Hospital Old Road, Headington Oxford United Kingdom OX3 7LJ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study Numbers:Bay g 5421/0740 and Bay g 5421/200031

Study information

Scientific Title

Acronym EDIT Study

Study objectives

The Early Diabetes Intervention Trial (EDIT) was a six-year, prospective, randomised, doubleblind, placebo-controlled study in subjects thought to be at increased risk of developing diabetes, and who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes could be delayed or prevented using an alpha-glucosidase inhibitor (acarbose) or a biguanide (metformin). The trial results were presented at the 2003 Diabetes UK meeting.

Ethics approval required

Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Prospective, randomised, double-blind, placebo-controlled study

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Not Specified

Participant information sheet

Health condition(s) or problem(s) studied Impaired glucose tolerance

Interventions

Subjects valid for inclusion were randomly assigned to acarbose 50 mg tds, metformin 500 mg tds, a combination of the two, or matching placebo.

Intervention Type Drug **Phase** Not Specified

Drug/device/biological/vaccine name(s) acarbose, metformin

Primary outcome measure Not provided at time of registration

Secondary outcome measures Not provided at time of registration

Overall study start date 01/01/1997

Completion date 31/12/2003

Eligibility

Key inclusion criteria

Subjects aged 30 to 70 years inclusive, with fasting hyperglycaemia; defined as a fasting plasma glucose (FPG) level ≥5.5 mmol/l and <7.8 mmol/l on two occasions at least 1 week apart

Participant type(s) Patient

Age group Adult

Sex Both

Target number of participants 631

Key exclusion criteria Not provided at time of registration

Date of first enrolment 01/01/1997

Date of final enrolment 31/12/2003

Locations

Countries of recruitment England

United Kingdom

Study participating centre Diabetes Trials Unit Oxford United Kingdom OX3 7LJ

Sponsor information

Organisation Bayer plc and Merck-Lipha (UK)

Sponsor details

-United Kingdom

Sponsor type Industry

Funder(s)

Funder type Industry

Funder Name Educational grants were provided by Bayer plc and Merck-Lipha (UK)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results				No	No
Abstract results				No	No
Abstract results	abstract 450-P	01/06/2000		No	No
Results article	results	01/06/2003		Yes	No
Results article	Hyper Glycaemia results	01/01/2009		Yes	No